Arcutis Biotherapeutics announced that its next-generation topical PDE4 inhibitor therapy for plaque psoriasis, ZORYVE cream 0.3%, has received regulatory approval from Health Canada. In Canada, ZORYVE is indicated for topical treatment of plaque psoriasis, including treatment of psoriasis in the intertriginous areas, in individuals 12 years of age and older.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ARQT:
- Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older
- Arcutis to Report First Quarter Financial Results
- Arcutis Biotherapeutics announces FDA acceptance of roflumilast foam NDA
- Arcutis to Present at Upcoming Investor Conference
- Arcutis Biotherapeutics price target lowered to $47 from $50 at Morgan Stanley
